Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Protagonist Therapeutics, Inc. (PTGX) has a Wall Street consensus price target of $111.75, based on estimates from 24 covering analysts. With the stock currently trading at $92.08, this represents a potential upside of +21.4%. The company has a market capitalization of $5.76B.
Analyst price targets range from a low of $108.00 to a high of $117.00, representing a 8% spread in expectations. The median target of $111.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 23 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PTGX trades at a trailing P/E of -44.9x and forward P/E of 25.4x. Analysts expect EPS to grow +276.8% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PTGX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for PTGX is $111.75, representing 21.4% upside from the current price of $92.08. With 24 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PTGX has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 23 Buy/Strong Buy ratings. The consensus 12-month price target of $111.75 implies 21.4% upside from current levels.
PTGX trades at a forward P/E of 25.4456x, representing a moderate valuation. With analysts targeting $111.75 (21.4% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $117 for PTGX, while the most conservative target is $108. The consensus of $111.75 represents the median expectation. These targets typically reflect 12-month expectations.
PTGX is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 23 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PTGX stock forecast based on 24 Wall Street analysts shows a consensus price target of $111.75, with estimates ranging from $108 (bear case) to $117 (bull case). The median consensus rating is "Buy".
PTGX trades at a forward P/E ratio of 25.4x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on PTGX, with a "Buy" consensus rating and $111.75 price target (21.4% upside). 23 of 24 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PTGX analyst price targets range from $108 to $117, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $111.75 consensus represents the middle ground.